ProMed BioSciences
ProMed BioSciences is a Cyprus-based biotech manufacturer of highly purified Type I collagen biomaterials — atelocollagen and telocollagen from porcine tendons — serving research institutions, cosmeceutical companies, and medical-device manufacturers via direct sales and US distribution partnerships.
- Company typePrivate
- Founded2017
- HeadquartersLimassol, Cyprus
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What ProMed BioSciences does
ProMed BioSciences (legal entity: Promed Bioscience Ltd) is a Cyprus-domiciled, privately held biotechnology company founded in 2017 in Limassol that manufactures and supplies highly purified medical-grade Type I collagen biomaterials — primarily atelocollagen and telocollagen — extracted from EU-sourced porcine tendon tissue. Its proprietary enzymatic and acid-based extraction processes preserve the protein's triple-helix structure and fibrillar nature, and the ultrapure grade applies dialysis purification to remove degradation byproducts; finished products are supplied in lyophilised form for chemical and thermal stability. The portfolio comprises four catalog SKUs (Atelocollagen PRO-2001, Telocollagen PRO-2002, Atelocollagen Ultrapure PRO-2003, and PRO-CUST custom formulations) plus the proprietary CollX3 triple atelocollagen complex marketed as the first European water-soluble atelocollagen complex.
The company sells into three end-markets: (i) research and academic institutions requiring purified collagen for 3D cell culture, tissue engineering scaffolds and cell-function assays, (ii) cosmeceutical and nutraceutical manufacturers incorporating collagen into skincare and joint-health products, and (iii) medical and clinical applications including wound care, dermal fillers, and surgical, dental and orthopaedic use cases. Distribution combines quote-based direct sales via the company website (PRO-CUST custom formulations) with US life-sciences distribution through Fisher Scientific US, LabViva, UnifiMed and Scientist.com, plus enterprise partnerships such as Maintrix (cosmeceuticals) and RSL Revolutionary Labs (oncology skincare).
The business model is B2B raw-material sales with custom formulation as a higher-margin service layer. Pricing is not publicly disclosed and is quote-based; standard products are offered in 10–100 mg pack sizes. The company's regulatory posture — ISO 9001:2015, ISO 13485:2016, GMP compliance, ISO 22442 alignment, and a completed viral inactivation validation aligned with ICH Q5 — is central to accessing regulated medical-device customers. Total disclosed funding is approximately €2.05 million across a 2022 round led by ASBIS Enterprises Plc and a 2025 round led by KV Fund II; revenue has not been disclosed. The operating headcount is small (1–10), with a founding team of three (Costas Pitsillides as CEO, Marianna Prokopi-Demetriades, and Telemachos Hassapis) and an advisory board member with prior leadership experience at Pfizer, Novartis, Sanofi-Pasteur-MSD, CUBIST and MSD/Merck plus research credentials at INSERM and NIH.
ProMed BioSciences firmographics
Firmographics- Name
- ProMed BioSciences
- Legal name
- Promed Bioscience Ltd
- Website
- https://promedbioscience.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- ProMed BioSciences is a Cyprus-based biotech manufacturer of highly purified Type I collagen biomaterials — atelocollagen and telocollagen from porcine tendons — serving research institutions, cosmeceutical companies, and medical-device manufacturers via direct sales and US distribution partnerships.
- Ownership category
- akta.pro rank
ProMed BioSciences industry classification
Industry- Product category
- Collagen Biomaterials
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Medical Equipment and Supplies Manufacturing (3391), Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers (42345)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047)
- akta.pro primary industry
- Collagen, Gelatin & Protein Hydrolysates (Animal-Derived) (AFANAGAI)
- akta.pro secondary industries
- Bioprocess Consumables & Reagents (resins, membranes, media components, buffers) (HLAAAJAI), Raw Materials & Critical Reagents Supply (Media/Resins/Cytokines) (HLAGAGAI), Biodegradable Medical & Hygiene Materials (absorbables, disposables substrates) (IMAEAOAL), Gelatin & Collagen Hydrolysates (Animal-Based Gelling Agents) (AFAJABAD), Bone & Cartilage Specialty Processing (Soup Bones, Marrow Bones, Tendons, Collagen-Rich Cuts) (AFANAJAH)
Keywords
Where ProMed BioSciences is headquartered
LocationHeadquarters
- HQ city
- Limassol
- HQ country
- Cyprus
- HQ region
- Europe
Offices2 records
Markets served
ProMed BioSciences business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Others
Revenue model
- Collagen Biomaterial Product Sales: Sale of standardized and custom collagen products (atelocollagen, telocollagen, ultrapure atelocollagen, custom formulations) for research, clinical, and cosmeceutical applications. Revenue generated through direct sales, distributor channels, and international partnerships.
- Custom Collagen Formulation Development: Development and sale of custom collagen formulations engineered to specific customer requirements for specialized applications. Both telocollagen and atelocollagen forms available with organic sourced or dialysis treated options.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | Standard collagen products (atelocollagen, telocollagen, ultrapure) available in pack sizes of 10-100mg |
Go-to-market motion3 records
Distribution channels5 records
Marketing channels5 records
ProMed BioSciences product offering
Product offeringCore offering
ProMed BioSciences manufactures and supplies highly purified, medical-grade Type I collagen biomaterials extracted from porcine tendons using proprietary enzymatic and acid-based methods. Its portfolio includes standardized atelocollagen, telocollagen, ultrapure atelocollagen, custom collagen formulations, and the proprietary CollX3 water-soluble triple atelocollagen complex, sold to research institutions, cosmeceutical manufacturers, and medical device companies worldwide.
Product overview
ProMed Bioscience is a biotech company that produces collagen-based biomaterials including highly purified medical-grade atelocollagen from porcine tissue. The product portfolio consists of four main catalog products (PRO-2001 Atelocollagen, PRO-2002 Telocollagen, PRO-2003 Atelocollagen Ultrapure, and PRO-CUST Collagen Custom Formulations) plus the proprietary CollX3 Triple Atelocollagen Complex. These products serve research, cosmeceutical, and medical applications including cell culture, tissue engineering, wound healing, and regenerative medicine. The company distributes internationally through various distribution channels.
Differentiator
Problem solved
Functional benefit
Brands
- CollX3: Innovative premium-grade atelocollagen formulation specifically designed for use as a raw material in dermaceutical and wound healing products. Features a triple-helix water-soluble atelocollagen sourced from porcine tendons with enhanced biocompatibility.
Products and services
- Atelocollagen (PRO-2001) Enzymatically extracted, lyophilized Type I atelocollagen with superior tensile strength and elasticity. Proprietary enzyme-based extraction removes telopeptides, reducing immunogenicity. Used by research labs for cell functional assays and soft 3D cell cultures.
- Telocollagen (PRO-2002) Acidically extracted, lyophilized Type I collagen that retains the fibrillar structure and physical/mechanical properties of native collagen. Suitable for in vitro cultures, 3D cell cultures with high stiffness, culture coatings, and tissue engineering scaffolds.
- Atelocollagen, Ultrapure (PRO-2003) Enzymatically extracted, dialyzed, and lyophilized Type I atelocollagen with enhanced biocompatibility and biodegradability. Complete removal of degradation byproducts via dialysis purification. Used for in vitro cell cultures, clinical research, wound healing, and cosmeceuticals.
- Collagen Custom Formulations (PRO-CUST) Custom-engineered collagen formulations in various configurations according to strict customer specifications. Available in both telocollagen and atelocollagen forms with options for organic-sourced or dialysis-treated variants for specialized applications.
- CollX3 Triple Atelocollagen Complex Proprietary water-soluble atelocollagen complex featuring triple-helix structure from porcine tendons, with three distinct molecular weights created through chemical, thermal, and mechanical modifications. Promotes wound healing, stimulates collagen and elastin production, and facilitates skin regeneration for dermaceutical and wound healing applications.
Quantifiable outcome
- Significant viral inactivation demonstrated across all tested viruses including highly resistant non-enveloped viruses (Rotavirus A, Porcine Parvovirus) through combined manufacturing process
- +1 more outcomes
Companies that use ProMed BioSciences
Customer profileNamed customers4 records
Segments3 records
Ideal customer profiles3 records
ProMed BioSciences technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
ProMed BioSciences partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered core and minor.
- Cyprus Institute of Neurology and Genetics (CING)coreStrategic collaboration for viral inactivation validation of Promed's medical-grade porcine-derived atelocollagen. CING served as the Knowledge Provider Organisation, providing specialized virology expertise and laboratory services to design and execute a comprehensive viral inactivation validation study aligned with ISO 22442 and ICH Q5 standards. Project ID: INNOVOUCHERS/0725/0019, funded by Cyprus Research and Innovation Foundation.
- MaintrixcoreStrategic collaboration for skincare technology using Promed's CollX3 proprietary water-soluble triple atelocollagen complex. Maintrix, a prominent cosmeceuticals manufacturer, will incorporate CollX3 into medical skincare products targeting skin regeneration and anti-aging applications. The partnership aims to bring innovative medical skincare solutions to consumers in 2024.
- Theramir LtdminorConsortium partner in the mediSKIN clinical trials project funded by the Research and Innovation Foundation (SEED/0719/0200). Theramir Ltd is part of a consortium including RSL Revolutionary Labs, Promed Bioscience, German Oncology Centre, and Cyprus University of Technology, developing medical-grade collagen complex products for cancer patients.
- German Oncology CentreminorClinical trials site for mediSKIN products developed using Promed Bioscience's novel collagen complex. Trials conducted for people diagnosed with breast cancer and head and neck cancer. Part of consortium funded by Research and Innovation Foundation (SEED/0719/0200).
- Cyprus University of TechnologyminorConsortium partner in mediSKIN clinical trials project (SEED/0719/0200) funded by the Research and Innovation Foundation. Contributes academic research expertise to the development of medical-grade collagen complex products for oncology patients.
- US Distributors (Fisher Scientific US, LabViva, UnifiMed, Scientist.com)corePromed's medical-grade collagen biomaterials made available through established US life sciences distribution platforms for research, clinical and cosmeceutical applications. UnifiMed is an Arizona-based full-scale commercial sales, marketing and distribution company specializing in medical diagnostics and biotech industries. The partnerships extend Promed's US coverage and commercial reach.
- Kinisis VenturescorePartnership with US-based business accelerator focused exclusively on identifying and preparing Cyprus-based companies to enter the United States market. Kinisis Ventures (KV Kinisis Ventures Fund RAIF V.C.I.C. Plc) is the first CySEC-registered Venture Capital fund focusing on Cypriot start-ups, leveraging US market experience to help capitalize disruptive Cypriot innovations. Promed is a Kinisis Ventures Fund I portfolio company.
- RSL Revolutionary Labs LtdcoreMemorandum of Understanding for joint development of collagen-based skincare products designed specifically for oncology patients. Promed's soluble 3D atelocollagen combined with RSL's proprietary blend of herbal extracts will result in medical-grade skincare products to address therapy side effects from chemotherapy, immunotherapy and radiation treatment, improving quality of life for cancer patients.
Scale indicators7 records
Recent moves6 records
Expansion highlights6 records
ProMed BioSciences competitors and assessment
Company assessmentBroad incumbents
- Integra LifeSciences: Large medical device company with a regenerative technologies portfolio (collagen-based wound care, dermal matrices, dural repair) — a broad incumbent in clinical collagen applications adjacent to ProMed's medical device customer base.
- Organogenesis Holdings: Public regenerative medicine company using collagen-based biomaterials in wound care and surgical applications — represents a much larger commercial competitor in the clinical collagen end-market.
- DSM Biomedical: Global biomaterials platform (parent of Collagen Solutions) supplying medical-grade collagen, hyaluronic acid, and other polymers to medical device and regenerative medicine customers — competes broadly with ProMed in the medical device raw material space.
Emerging players
- BioLamina AB: Specializes in laminin and other defined ECM proteins for cell culture and stem cell research, with a similar high-purity research biomaterials positioning that overlaps with ProMed's research customer base.
- EnColl Corporation: Producer of Type I atelocollagen and other collagen forms for cosmetic, cell culture, and tissue engineering uses — a smaller specialty player with significant product and customer overlap with ProMed.
- Xylyx Bio (formerly Kyeron): Develops tissue-specific extracellular matrix and collagen-based substrates for regenerative medicine and drug discovery, with a similar niche focus on high-purity, native-structure collagen for research and clinical applications.
Regional players
- Koken Co., Ltd. Japanese manufacturer of medical-grade collagen products (atelocollagen solutions, sponges, sheets) for research, cosmetics, and clinical use — a comparable specialist collagen producer with similar product formats, primarily serving Asian markets.
Direct peers
- CellSystems GmbH (Collagen Solutions): Supplier of collagen and ECM coatings/gels for cell culture and tissue engineering research — competes in the same research-grade collagen category that ProMed serves via Fisher Scientific and similar channels.
- Collagen Matrix Inc. Manufacturer of medical-grade collagen and mineral-based biomaterials for orthopedic, dental, wound care, and tissue engineering applications — directly comparable in medical device raw material positioning.
- Advanced BioMatrix: US-based manufacturer of collagen products (atelocollagen, telocollagen, hydrogels) for 3D cell culture, tissue engineering, and regenerative medicine research — directly overlapping with ProMed's research and biomaterial portfolio.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
ProMed BioSciences social profiles
Digital presenceProMed BioSciences compliance and trust
Trust signalCompliance6 records
ProMed BioSciences financial estimates
Financial estimateRevenue estimate
Valuation estimate
ProMed BioSciences leadership team
Management profileNumber of profiles
Profiles4 records
ProMed BioSciences funding detail
Funding detailFunding overview
Funding rounds3 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
ProMed BioSciences M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about ProMed BioSciences
What does ProMed BioSciences do?
ProMed BioSciences manufactures and supplies highly purified, medical-grade Type I collagen biomaterials extracted from porcine tendons using proprietary enzymatic and acid-based methods. Its portfolio includes standardized atelocollagen, telocollagen, ultrapure atelocollagen, custom collagen formulations, and the proprietary CollX3 water-soluble triple atelocollagen complex, sold to research institutions, cosmeceutical manufacturers, and medical device companies worldwide.
Is ProMed BioSciences a public or private company?
ProMed BioSciences is a private company. It is classified as venture growth investor backed and is currently operating.
When was ProMed BioSciences founded?
ProMed BioSciences was founded in 2017. It employs 1 to 10 people.
Where is ProMed BioSciences based?
ProMed BioSciences is headquartered in Limassol, Cyprus, in the Europe region.
How does ProMed BioSciences make money?
Two revenue lines are on record. Collagen Biomaterial Product Sales are the primary driver. The others are custom Collagen Formulation Development.
Who are ProMed BioSciences's main competitors?
Broad incumbents on record are Integra LifeSciences, Organogenesis Holdings and DSM Biomedical. Emerging players are BioLamina AB, EnColl Corporation and Xylyx Bio (formerly Kyeron). Koken Co., Ltd. is listed as a regional player. Direct peers are CellSystems GmbH (Collagen Solutions), Collagen Matrix Inc. and Advanced BioMatrix.
Does ProMed BioSciences have an API?
No public API is recorded for ProMed BioSciences.
What industry is ProMed BioSciences in?
ProMed BioSciences's product category is Collagen Biomaterials. Its primary akta.pro industry code is AFANAGAI, Collagen, Gelatin & Protein Hydrolysates (Animal-Derived), with a secondary code of HLAAAJAI, Bioprocess Consumables & Reagents (resins, membranes, media components, buffers). Its NAICS code is 325414 and its SIC code is 2836.